Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells

Anti-Cancer Drugs

Volumn 25, Issue 4, 2014, Pages 393-405

  Alupei, Marius C ^a   Licarete, Emilia ^a   Cristian, Flavia B ^a   Banciu, Manuela ^a  

^a BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

Hypoxia inducible factor 1 ; Lipophilicity; Melanoma cells; Oxidative stress; Statin

Indexed keywords

ANGIOGENIC PROTEIN; ANTIOXIDANT; FLUORESCEIN ISOTHIOCYANATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOCORTIN 5; MEVINOLIN; PRAVASTATIN; PROPIDIUM IODIDE; SIMVASTATIN; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROPHILICITY; IN VITRO STUDY; INFLAMMATION; LIPOPHILICITY; MELANOMA CELL; MURINAE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; NECROSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PRAVASTATIN; SIMVASTATIN;

EID: 84896365351     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000065     Document Type: Article

References (53)

1. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 1988; 36 (Suppl 3): 72-82. (Pubitemid 19169923)
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
3. Grodos D, Tonglet R. Scandinavian simvastatin study (4S). Lancet 1994; 344:1768.
4. Massy ZA, Guijarro C. Statins: effects beyond cholesterol lowering. Nephrol Dial Transplant 2001; 16: 1738-1741. (Pubitemid 32821398)
5. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005; 5: 579-594. (Pubitemid 41789598)
6. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003; 90: 317-321. (Pubitemid 37087893)
7. Coimbra M, Banciu M, Fens MH, de Smet L, Cabaj M, Metselaar JM, et al. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release 2010; 148: 303-310.
8. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118. (Pubitemid 40261799)
9. Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 2002; 9: 493-504. (Pubitemid 34521177)
10. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000; 103: 227-238.
11. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelinconverting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89: 583-590. (Pubitemid 32924212)
12. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273:24266-24271. (Pubitemid 28435775)
13. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23: 482-486. (Pubitemid 35279610)
14. Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett 2010; 199: 277-287.
15. Elewa HF, El-Remessy AB, Somanath PR, Fagan SC. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy 2010; 30: 169-176.
16. Minichsdorfer C, Hohenegger M. Autocrine amplification loop in statininduced apoptosis of human melanoma cells. Br J Pharmacol 2009; 157: 1278-1290.
17. Zhao W, Liu H, Xu S, Entschladen F, Niggemann B, Zanker KS, et al. Migration and metalloproteinases determine the invasive potential of mouse melanoma cells, but not melanin and telomerase. Cancer Lett 2001; 162 (Suppl):S49-S55.
18. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with tolllike receptor agonists as a treatment for melanoma. PLoS One 2009; 4:e7334.
19. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A 2009; 106: 7957-7961.
20. Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer 2009; 8:104.
21. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012; 2012:354191.
22. Ledezma E, Wittig O, Alonso J, Cardier JE. Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells. Melanoma Res 2009; 19: 69-74.
23. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 2008; 8:9.
24. Favero GM, FO M, Oliveira KA, Bohatch MS Jr, Borelli P, Barros FE, et al. Simvastatin impairs murine melanoma growth. Lipids Health Dis 2010; 9:142.
25. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218: 474-475. (Pubitemid 12000901)
26. Ishiyama M, Sasamoto K, Shiga M, Ohkura Y, Ueno K. Novel disulfonated tetrazolium salt that can be reduced to a water-soluble formazan and its application to the assay of lactate dehydrogenase. Analyst 1995; 120: 113-116.
27. Van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9. (Pubitemid 28050057)
28. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949; 177: 751-766.
29. Banciu M, Schiffelers RM, Fens MH, Metselaar JM, Storm G. Antiangiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release 2006; 113: 1-8. (Pubitemid 43818165)
30. Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic Res 1996; 25: 57-74. (Pubitemid 26245475)
31. Ukeda H, Shimamura T, Tsubouchi M, Harada Y, Nakai Y, Sawamura M. Spectrophotometric assay of superoxide anion formed in Maillard reaction based on highly water-soluble tetrazolium salt. Anal Sci 2002; 18: 1151-1154.
32. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 2011; 336: 496-505.
33. Gorlach A, Bonello S. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J 2008; 412:e17-e19.
34. Laderoute KR. The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. Semin Cell Dev Biol 2005; 16: 502-513. (Pubitemid 41247873)
35. Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi L, et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 2011; 6:e28813.
36. Ivanov VN, Hei TK. Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis 2011; 16: 1268-1284.
37. Zhao WX, Tang SS, Jin X, Zhang CM, Zhang T,Wang CC, et al. Olaquindoxinduced apoptosis is suppressed through p38 MAPK and ROS-mediated JNK pathways in HepG2 cells. Cell Biol Toxicol 2013; 29: 229-238.
38. Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N. MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes. Proc Natl Acad Sci U S A 1999; 96: 15127-15132. (Pubitemid 30019776)
39. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, et al. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol 2008; 142: 775-785.
40. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654. (Pubitemid 39193744)
41. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
42. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70: 1469-1480.
43. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010; 46: 1159-1169.
44. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005; 65: 999-1006. (Pubitemid 40216462)
45. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)- 1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res 2001; 61: 7349-7355. (Pubitemid 32946535)
46. Zhou A, Scoggin S, Gaynor RB,Williams NS. Identification of NF-kappa Bregulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene 2003; 22: 2054-2064. (Pubitemid 36523642)
47. Mann DA, Trim J, Smart D,Wright MC, Arthur MJP, Samten B, et al. Control of TIMP-1 gene transcription in hepatic myofibroblasts by a combination of AP-1 proteins and novel transcription factors. Int J Exp Pathol 2000; 81:A18-A19.
48. Samten B, Townsend JC, Weis SE, Bhoumik A, Klucar P, Shams H, et al. CREB, ATF, and AP-1 transcription factors regulate IFN-gamma secretion by human T cells in response to mycobacterial antigen. J Immunol 2008; 181: 2056-2064.
49. Sgadari C, Farber JM, Angiolillo A, Liao F, Teruya-Feldstein J, Burd PR, et al. Mig, the monokine induced by interferon-g, promotes tumor necrosis in vivo. Blood 1997; 89: 2635-2643. (Pubitemid 27172547)
50. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-258. (Pubitemid 39061608)
51. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176. (Pubitemid 44311072)
52. Martin KR, Barrett JC. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol 2002; 21: 71-75. (Pubitemid 34591267)
53. Celec P, Behuliak M. The lack of non-steroid isoprenoids causes oxidative stress in patients with mevalonic aciduria. Med Hypotheses 2008; 70: 938-940. (Pubitemid 351400711)